Recruiting
A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) - CA116-003
Updated:
17 July, 2023
|
ClinicalTrials.gov
Phase
Gender(s)
Age Range
Location(s)
Recruiting
Inclusion Criteria: - Histologically or cytologically documented metastatic NSCLC AC (as defined by the 8th International Association for the Study of Lung Cancer Classification). - Measurable target disease assessed by the investigator according to RECIST 1.1. - Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 Exclusion Criteria: - NSCLC histologies other than AC (ie, squamous cell carcinoma, large cell carcinoma). - Significant third-space fluid retention (eg, ascites or pleural effusion) that requires repeated drainage. - Prior pneumonectomy. Prior lobectomy and segmentectomy are allowed > 12 months before treatment. - Recent chest radiotherapy. Participants with chest or chest wall radiation may be permitted if chest radiation is documented > 6 months before starting study treatment. Other protocol-defined inclusion/exclusion criteria apply.
If you want to report a side effect, you can report directly to the Danish Medicines Agency via the website www.meldenbivirkning.dk
We recommend that you also contact BMS to report side effects.
Side effects and other reportable events are defined here
Report side effects or product quality complaints: Medical Information
466-DK-2200001